| Literature DB >> 35804985 |
Peter Tschann1, Markus P Weigl1, Daniel Lechner1, Christa Mittelberger1, Tarkan Jäger2, Ricarda Gruber2, Paolo N C Girotti1, Christof Mittermair3, Patrick Clemens4, Christian Attenberger5,6, Philipp Szeverinski6, Thomas Brock1, Jürgen Frick1, Klaus Emmanuel2, Ingmar Königsrainer1, Jaroslav Presl2.
Abstract
BACKGROUND: Robotic surgery represents a novel approach for the treatment of colorectal cancers and has been established as an important and effective method over the last years. The aim of this work was to evaluate the effect of a robotic program on oncological findings compared to conventional laparoscopic surgery within the first three years after the introduction.Entities:
Keywords: laparoscopic surgery; oncological findings; quality of resection; robotic assisted surgery
Year: 2022 PMID: 35804985 PMCID: PMC9264883 DOI: 10.3390/cancers14133208
Source DB: PubMed Journal: Cancers (Basel) ISSN: 2072-6694 Impact factor: 6.575
Figure 1Operation time trend decreased with number of performed cases.
Patients’ characteristics.
| Entire Cohort | Propensity-Score-Matched Cohort | |||||
|---|---|---|---|---|---|---|
| LR Group | RR Group | LR Group | RR Group | |||
| Sex, male/female, | 44 (53.66%)/38 (46.34%) | 60 (64.52%)/33 (35.48%) | 0.144 | 38 (60.32%)/25 (39.68%) | 37 (58.73%)/26 (41.27%) | 0.856 |
| Age, median (IQR), y | 64.0 (58.0–75.0) | 68.0 (60.0–75.0) | 0.438 | 65.0 (60.0–78.0) | 70.0 (62.0–76.0) | 0.519 |
| BMI, median (IQR), kg/m2 | 25.4 (23.0–29.0) | 25.1 (23.0–28.0) | 0.654 | 25.0 (23.0–28.0) | 24.7 (22.0–28.0) | 0.583 |
| ASA (average), | 0.122 | 0.222 | ||||
| I | 3 (3.66%) | 12 (12.9%) | 3 (4.76%) | 9 (14.29%) | ||
| II | 39 (47.56%) | 41 (44.09%) | 29 (46.03%) | 25 (39.68%) | ||
| III | 39 (47.56%) | 40 (43.01%) | 30 (47.62%) | 29 (46.03%) | ||
| IV | 1 (1.22%) | 0 (0.0%) | 1 (1.59%) | 0 (0.0%) | ||
| V | 0 | 0 | 0 | 0 | ||
| Tumor localization, | ||||||
| Right | 19 (23.75%) | 13 (13.98%) | 0.116 | 13 (21.31%) | 10 (15.87%) | 0.489 |
| Left (+upper rectum) | 19 (23.75%) | 20 (21.51%) | 0.792 | 14 (22.95%) | 16 (25.4%) | 0.676 |
| Rectum (mid, low rectum) | 42 (52.5%) | 60 (64.52%) | 0.075 | 34 (55.74%) | 37 (58.73%) | 0.473 |
| CEA level preoperative, median (IQR), µg/L | 2.4 (1.0–4.0) | 2.1 (1.0–4.0) | 0.468 | 2.6 (2.0–4.0) | 2.2 (1.0–4.0) | 0.425 |
| Previous abdominal surgery, | 18 (21.95%) | 32 (34.41%) | 0.056 | 13 (20.63%) | 22 (34.92) | 0.037 |
| Comorbidities, | 0.091 | 0.066 | ||||
| Yes | 27 (32.93%) | 41 (45.56%) | 19 (30.16%) | 28 (46.67%) | ||
| No | 55 (67.07%) | 49 (54.44%) | 44 (69.84%) | 32 (53.33%) | ||
| Comorbidities, % | 0.328 | 0.351 | ||||
| Coronary disease | 24.39% | 13.98% | 26.98% | 14.29% | ||
| Pulmonary insufficiency | 4.88% | 6.45% | 6.35% | 4.76% | ||
| Obesity | 8.54% | 11.83% | 4.76% | 9.52% | ||
| Kidney disease | 9.76% | 7.53% | 4.76% | 4.76% | ||
| Hypertension | 39.02% | 37.63% | 44.44% | 33.33% | ||
| Chronic renal failure | 3.66% | 2.15% | 4.76% | 1.59% | ||
| Insult | 4.88% | 2.15% | 6.35% | 1.59% | ||
| Atrial fibrillation | 7.32% | 4.3% | 9.52% | 4.76% | ||
| Clinical stage (UICC), | 0.611 | 0.459 | ||||
| I | 18 (29.03%) | 17 (23.94%) | 6 (22.22%) | 6 (42.86%) | ||
| II | 26 (41.94%) | 25 (35.21%) | 10 (37.04%) | 4 (28.57%) | ||
| III | 17 (27.42%) | 28 (39.44%) | 11 (40.74%) | 4 (28.57%) | ||
| Preoperative therapy (rectal cancer), | 0.344 | 0.07 | ||||
| Short-term (5 × 5Gy) | 3 (3.66%) | 2 (2.15%) | 3 (4.76%) | 1 (1.59%) | ||
| Long-term (50.4 Gy + Chemotherapy) | 18 (21.95%) | 27 (29.03%) | 15 (23.81%) | 15 (23.81%) | ||
IQR = interquartile range, BMI = body mass index, ASA = American Society of Anesthesiologists, CEA = carcinoembryonic antigen, UICC = Union Internationale Contre le Cancer. Values are given as median and IQR (interquartile range) or numbers and percentage.
Operative method, perioperative results and postoperative complications.
| Entire Cohort | Propensity-Score-Matched Cohort | |||||
|---|---|---|---|---|---|---|
| LR Group | RR Group | LR Group | RR Group | |||
| Operative method, | 0.14 | 0.397 | ||||
| Right | 19 (23.17%) | 13 (13.98%) | 14 (22.22%) | 10 (15.87%) | ||
| Left (+upper rectum) | 19 (23.75%) | 20 (21.51%) | 14 (22.95%) | 16 (25.4%) | ||
| Rectum (mid, low rectum) | 42 (52.5%) | 60 (64.52%) | 33 (52.38%) | 37 (58.73%) | ||
| Transverse | 2 (2.44%) | 0 (0%) | 2 (3.17%) | 0 (0%) | ||
| Anastomosis | <0.001 | 0.008 | ||||
| S-S | 21 (25.61%) | 13 (13.98%) | 15 (28.3%) | 11 (18.97%) | ||
| E-E | 31 (37.8%) | 26 (27.96%) | 24 (45.28%) | 16 (27.59%) | ||
| S-E | 16 (19.51%) | 46 (49.46%) | 12 (22.64%) | 30 (51.72%) | ||
| Colo-anal | 2 (2.44%) | 2 (2.15%) | 2 (3.77%) | 1 (1.72%) | ||
| Intracorporeal/extracorporeal (right hemicolectomy), | 0.008 | 0.11 | ||||
| extracorporeal | 14 (73.68%) | 3 (23.07%) | 10 (15.87%) | 3 (4.76%) | ||
| intracorporeal | 5 (26.31%) | 10 (76.92%) | 3 (4.76%) | 6 (9.52%) | ||
| Protective defunctioning stoma, | 16 (32%) | 39 (55.7%) | 0.006 | 20 (31.7%) | 37 (58.73%) | 0.03 |
| Operation time, median (IQR), min | 200.0 (150.0–243.0) | 204.0 (174.0–278.0) | 0.045 | 205.0 (154.0–244.0) | 193.0 (158.0–252.0) | 0.915 |
| Time to first flatus, median (IQR), d | 2.0 (1.0–2.0) | 2.0 (1.0–2.0) | 0.803 | 2.0 (1.0–2.0) | 2.0 (1.0–2.0) | 0.768 |
| Hb preoperative, median (IQR), g/l | 13.4 (12.0–15.0) | 13.2 (12.0–14.0) | 0.493 | 13.3 (12.0–14.0) | 13.3 (12.0–15.0) | 0.757 |
| Hb postoperative, median (IQR), g/l | 11.65 (10.0–13.0) | 11.3 (10.0–12.0) | 0.242 | 11.8 (10.0–13.0) | 11.3 (10.0–12.0) | 0.468 |
| Complications, | 18.29% | 21.51% | 0.596 | 19.05% | 15.87% | 0.639 |
| Anastomotic leakage | 4 (4.88%) | 4 (4.3%) | 3 (4.76%) | 2 (3.17%) | ||
| Wound infection | 4 (4.88%) | 3 (3.23%) | 3 (4.76%) | 2 (3.17%) | ||
| Bleeding | 1 (1.22%) | 2 (2.15%) | 1 (1.59%) | 0 (0.0%) | ||
| Intra-abdominal abscess/infection | 1 (1.22%) | 2 (2.15%) | 1 (1.59%) | 1 (1.59%) | ||
| Bowel obstruction | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| Renal dysfunction | 0 (0%) | 1 (1.08%) | 0 (0%) | 1 (1.59%) | ||
| Others * | 5 (6.1%) | 8 (8.6%) | 4 (6.35%) | 4 (6.35%) | ||
| Clavien–Dindo Classification, | 0.855 | 0.912 | ||||
| I | 1 (1.22%) | 3 (3.23%) | 1 (1.59%) | 1 (1.59%) | ||
| II | 7 (8.54%) | 8 (8.6%) | 5 (7.94%) | 4 (6.35%) | ||
| III | 6 (7.32%) | 7 (7.53%) | 5 (7.94%) | 3 (4.76%) | ||
| IV | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | ||
| V | 1 (1.22%) | 2 (2.15%) | 1 (1.59%) | 2 (3.17%) | ||
| Conversion to open procedure, | 16 (19.51%) | 5 (5.38%) | 0.004 | 13 (20.63%) | 3 (4.76%) | 0.006 |
| Stoma reversal time, median (IQR), d | 75.5 (65.0–394.0) | 78.0 (31.0–110.0) | 0.339 | 220.5 (73.0–464.0) | 70.0 (22.0–83.0) | 0.068 |
| Duration of hospital stay, median (IQR) | 9.0 (7.0–14.0) | 9.0 (6.0–13.0) | 0.928 | 9.0 (7.0–14.0) | 9.0 (6.0–12.0) | 0.149 |
IQR = interquartile range, Hb = hemoglobin, S-S = side to side, E-E = end to end, S-E = side to end. Values are given as median and IQR (interquartile range) or numbers and percentage. * Including urinary infection/retention, pulmonary and cardiac complications.
Histopathological findings, specimen score and number of retrieved lymph nodes.
| Entire Cohort | Propensity-Score-Matched Cohort | |||||
|---|---|---|---|---|---|---|
| LR Group | RR Group | LR Group | RR Group | |||
| Pathological T Stage, | 0.834 | 0.896 | ||||
| Tis | 2 (2.47%) | 6 (6.45%) | 1 (1.59%) | 2 (3.17%) | ||
| T1 | 15 (18.52%) | 16 (18.18%) | 12 (19.05%) | 12 (19.05%) | ||
| T2 | 29 (35.36%) | 27 (30.68%) | 24 (38.1%) | 20 (31.75%) | ||
| T3 | 32 (39.51%) | 40 (43.01%) | 24 (38.1%) | 25 (39.68%) | ||
| T4 | 4 (4.94%) | 4 (4.55%) | 2 (3.17%) | 3 (4.76%) | ||
| Pathological N Stage, | 0.22 | 0.847 | ||||
| N0 | 60 (73.17%) | 60 (64.51%) | 44 (69.84%) | 43 (68.25%) | ||
| N+ | 22 (27.16%) | 33 (35.87%) | 19 (30.16%) | 20 (31.75%) | ||
| Postoperative UICC Stage, | 0.225 | 0.295 | ||||
| 0 | 3 (3.66%) | 6 (6.45%) | 1 (1.59%) | 2 (3.17%) | ||
| I | 34 (41.46%) | 33 (35.87%) | 27 (42.86%) | 26 (41.27%) | ||
| II | 20 (24.39%) | 18 (19.57%) | 15 (23.81%) | 12 (19.05%) | ||
| III | 25 (30.49%) | 31 (33.7%) | 20 (31.75%) | 20 (31.75%) | ||
| IV | 0 (0%) | 5 (5.43%) | 0 (0%) | 3 (4.76%) | ||
| Mercury Score, | 0.355 | 0.343 | ||||
| I | 52 (86.67%) | 52 (88.14%) | 39 (84.78%) | 34 (85.0%) | ||
| II | 6 (10.0%) | 7 (11.86%) | 5 (10.87%) | 6 (15.0%) | ||
| III | 2 (3.33%) | 0 (0.0%) | 2 (4.35%) | 0 (0.0%) | ||
| Number of retrieved lymph nodes, median (IQR) | 22.0 (16.0–27.0) | 24.0 (15.0–30.0) | 0.512 | 22.0 (16.0–26.0) | 23.0 (15.0–28.0) | 0.942 |
IQR = interquartile range, UICC = Union Internationale Contre le Cancer. Values are given as median and IQR (interquartile range) or numbers and percentage.